Latest news
Akeso (SEHK:9926) Dosed Its First AK138D1 Patient, Is The 47% Undervalued View Too Bullish? - simplywall.stsimplywall.st · Mon, 03 Aug 2026 11:28:26 GMTAkeso, Inc. Revenue Breakdown – HKEX:9926 - TradingViewTradingView · Sat, 01 Aug 2026 09:07:44 GMTPositive Report for Akeso, Inc. (9926) from Nomura - theglobeandmail.comtheglobeandmail.com · Wed, 29 Jul 2026 00:34:00 GMTAkeso Number of Employees 2026 | Employee Count & Headcount Data - Revelio LabsRevelio Labs · Tue, 28 Jul 2026 15:08:12 GMTAkeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTSummit, Merck must navigate new regulatory terrain in China-first cancer landscape - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMTNomura Adjusts Akeso's Price Target to HK$138.29 From HK$142.50, Keeps at Buy - marketscreener.commarketscreener.com · Mon, 27 Jul 2026 07:00:00 GMT